Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZR2 followed by RCHOP in elderly newly-diagnosed DLBCL
NCT05290090Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2021
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Zhejiang Cancer Hospital. Started Oct 2021; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05290090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05290090.